|
|
Post by harryx1 on Oct 9, 2019 13:01:46 GMT -5
|
|
|
|
Post by slugworth008 on Oct 9, 2019 15:23:33 GMT -5
Right? Just like everything MNKD - It's just another WTF item. I'm really starting to think that MC has served his purpose and it's time to upgrade. JMHO |
|
|
|
Post by lakers on Oct 9, 2019 17:09:12 GMT -5
I did communicate with MC about CF on and off over several years. Most funding was devoted to A, leaving little left for anything else (rationing). That was a mistake. Mnkd could have multi-tasked and spread out spending over several pipeline compounds. It’s always been giving A a majority of funding another year; next year will be A year. BoD should have been more involved...
|
|
|
|
Post by letitride on Oct 9, 2019 18:53:11 GMT -5
One in the hand vs two in the bush. Im down with having a floor under Mannkind to run on before we chase after a few more in the bush. I believe MC has been picking off his ducks in good order. If he is holding out for another UTHR type deal at the moment, instead of spreading Mannkind thinner Im down with it.
|
|
|
|
Post by falconquest on Oct 9, 2019 19:28:20 GMT -5
Mike was hired as Chief Commercialization Officer......because that is his specialty.......I'm still waiting!
|
|
|
|
Post by letitride on Oct 9, 2019 19:42:58 GMT -5
Mike was hired as Chief Commercialization Officer......because that is his specialty.......I'm still waiting! Whose the was and I am believing that position would be advisory at this point if Mannkind is going to go forward with another molecule. Or maybe the unknown with UTHR. |
|
|
|
Post by audiomr on Oct 12, 2019 16:02:40 GMT -5
When Edstrom said that the expectation was that money would be pouring in from Afrezza. In light of what actually happened, it's hard to see how MC could have applied significant resources to other compounds without endangering the company or saddling us with even more dilution than we've already experienced. Afrezza was the only drug Mannkind had that could generate revenue in the near term. Seems to me that focusing the company's limited funds on Afrezza was the only reasonable call. |
|
|
|
Post by mnholdem on Oct 13, 2019 7:05:17 GMT -5
Michael Castagna was MannKind's Chief Commercial Officer at the time wasn't he?
|
|
|
|
Post by audiomr on Oct 14, 2019 17:43:39 GMT -5
Michael Castagna was MannKind's Chief Commercial Officer at the time wasn't he? Afrezza was launched early in 2015, just shy of 5 years ago. Castagna wasn't around then. I don't think he was hired until after the Sanofi divorce. |
|
|
|
Post by mnholdem on Oct 14, 2019 19:10:32 GMT -5
Al Mann was CEO for the Agreement. Matt Pfeffer was when Sanofi gave it back. His first hire was Mike Castagna. Pfeffer got $175M in settlement. More than enough for a successful relaunch if he’d hired the right person for the job, IMO.
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Oct 14, 2019 19:10:34 GMT -5
Michael Castagna was MannKind's Chief Commercial Officer at the time wasn't he? Afrezza was launched early in 2015, just shy of 5 years ago. Castagna wasn't around then. I don't think he was hired until after the Sanofi divorce. Mike has been with the company just over 3+ years. Year 1 as CCO and 2 as CEO. |
|
|
|
Post by nylefty on Oct 14, 2019 19:21:17 GMT -5
Pfeffer got $175M in settlement. Is that a typo? If not, where did your information come from? |
|
|
|
Post by compound26 on Oct 14, 2019 19:54:23 GMT -5
Al Mann was CEO for the Agreement. Matt Pfeffer was when Sanofi gave it back. His first hire was Mike Castagna. Pfeffer got $175M in settlement. More than enough for a successful relaunch if he’d hired the right person for the job, IMO. The settlement consists mostly a forgiveness of obligations owed by Mannkind to Sanofi in their partnership. To my recollection, Mannkind only got around $40 million cash via an insulin put, which was part of the settlement. Additionally, to my recollection, the total amount of settlement was in the neighborhood of $120 million (see the announcement below), not $175 million (though under the license agreement between Mannkind and Sanofi, Sanofi did agree to advance to MannKind its share of the collaboration’s expenses up to a limit of $175 million investors.mannkindcorp.com/news-releases/news-release-details/sanofi-and-mannkind-announce-global-licensing-agreement-afrezzar). www.globenewswire.com/news-release/2016/11/10/888582/0/en/MannKind-and-Sanofi-Reach-Agreement-on-AFREZZA.htmlVALENCIA, Calif., Nov. 09, 2016 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) (TASE:MNKD) today announced that MannKind and Sanofi have entered into an agreement with the following terms: The promissory note and security agreement between MannKind and Aventisub LLC, a Sanofi affiliate, are terminated, with Aventisub agreeing to forgive the full outstanding loan balance of $71.56 million. MannKind is also relieved from its obligation to pay $0.5 million in previously uncharged costs related to the collaboration. Sanofi will purchase $10.2 million worth of insulin from MannKind in early December as part of its preexisting commitment to purchase insulin following termination of the collaboration and MannKind’s exercise of a “put” option. The balance of the insulin “put” option ($30.6 million) is accelerated with Sanofi completing the cash payment of $30.6 million to MannKind by January 9, 2017. This payment will be made without MannKind being required to deliver any insulin to Sanofi. All issues arising out of the license and collaboration agreement, the supply agreement, the promissory note, the security agreement and the transition agreement are resolved. |
|
|
|
Post by harryx1 on Oct 30, 2019 14:29:30 GMT -5
|
|
|
|
Post by longliner on Oct 30, 2019 22:32:51 GMT -5
|
|
